Synapse - Works

Results (5712)

Tenacity: A phase 2, multicenter, open-label, single-arm study of AL101 monotherapy in patients with notch-activated triple negative breast cancer

Meeting Abstract

Traina, T. A.; Cobain, E. F.; Evron, E.; Duksin, C.; Gordon, G.
Cancer Research (2021)

Fulltext@MSK | Save

Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)

Meeting Abstract

Turner, N.; Jhaveri, K.; Kalinsky, K.; Loibl, S.; Loi, S.; Im, S. A.; Saura, C.; Schmid, P.; Schutzman, J. L.; Stout, T. J.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Inflammation and coagulation biomarkers associated with physical resilience in older women receiving chemotherapy for early breast cancer

Meeting Abstract

Sedrak, M. S.; Sun, C.; Muss, H.; Freedman, R. A.; Magnuson, A.; Gross, C. P.; Tew, W. P.; Klepin, H. D.; Wildes, T. M.; Dotan, E.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Outcomes for metaplastic breast cancer differ by histologic subtype

Meeting Abstract

Tadros, A. B.; Sevilimedu, V.; Zabor, E.; Giri, D.; Morrow, M.; Plitas, G.
Cancer Research (2021)

Fulltext@MSK | Save

Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane

Meeting Abstract

O'Shaughnessy, J.; Schwartzberg, L.; Piccart, M.; Rugo, H. S.; Yardley, D. A.; Cortes, J.; Untch, M.; Harbeck, N.; Wright, G. S.; Bondarenko, I.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) ± palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)

Meeting Abstract

Olivera, M.; Jhaveri, K.; Juric, D.; Bedard, P. L.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Emerging from COVID-19 pandemic: Provider perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer

Meeting Abstract

Park, K. U.; Gregory, M. E.; Lustberg, M. B.; Bazan, J. G.; Shen, C.; Rosenberg, S. M.; Blinder, V. S.; Sharma, P.; Pusztai, L.; Partridge, A. H.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer

Meeting Abstract

Rosen, E. Y.; Italiano, A.; Juric, D.; Reeves, J. A.; Dima, L.; Brega, N.; Drilon, A.
Cancer Research (2021)

Fulltext@MSK | Save

Early intervention for and management of alpelisib (ALP)-induced hyperglycemia: Case studies from the phase III SOLAR-1 trial

Meeting Abstract

Mayer, I.; Farooki, A.; Rugo, H. S.; Iwata, H.; Ciruelos, E.; Campone, M.; Loibl, S.; Conte, P.; Juric, D.; Ghaznawi, F.; more...
Cancer Research (2021)

Fulltext@MSK | Save

A phase Ib trial of fulvestrant + CDK4/6 inhibitor (CDK4/6i) palbociclib + pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR-amplified/ ER+/ HER2-negative metastatic breast cancer (MBC)

Meeting Abstract

Mayer, I. A.; Haley, B. B.; Abramson, V. G.; Brufsky, A.; Rexer, B.; Stringer-Reasor, E.; Jhaveri, K. L.; Sanders, M.; Ericsson-Gonzalez, P. I.; Ye, F.; more...
Cancer Research (2021)

Fulltext@MSK | Save